comprehensive -WSS

comprehensive

author：leisure time 2025-09-30 14:08:15 - browse：87543

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Celiac disease study examines precisely how gluten triggers injury

hotspot

leisure time

WSS

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Bring on the sabbaticals for nurses

Celiac disease study examines precisely how gluten triggers injury

Congress: Eradicate hepatitis C and reduce the deficit

Testing GLP

Chinese researcher claims birth of first gene

Wikipedia

comprehensive

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Global childhood vaccinations edge closer to pre

Walensky prepares to leave CDC — and Congress — behind

Mike Pence clashes with Tucker Carlson in Iowa

Apple is now the first public company to be valued at $3 trillion

Who gets to use the title 'doctor'?

Supreme Court strikes down use of affirmative action

J&J expands global access to TB drug amid advocacy campaign

Duchenne breakthrough therapy leaves behind pioneering families

Biotech investment managers search for lucrative opportunities

leisure time

CRISPR technology availability, affordability needs to be expanded

6 surprising facts about sugar

Cancer, immunology, HIV research ensnared in fetal tissue politics

Global childhood vaccinations edge closer to pre

Medicare Advantage insurers pressure Biden for bigger payments

Grail faces three suits alleging harassment, retaliation

hotspot

leisure time

hotspot

focus